[Ip-health] Dr. June in NYT in 2012, used $20k as cost of engineered T-cells
gmcfiar at gmail.com
Fri Sep 1 13:48:35 PDT 2017
I’m sure they spend $2-3 BILLION on all that other stuff!
From the article:
In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million. <https://en.wikipedia.org/wiki/Kite_Pharma#cite_note-40> <https://en.wikipedia.org/wiki/Kite_Pharma#cite_note-41> <https://en.wikipedia.org/wiki/Kite_Pharma#cite_note-42> The company listed on the NASDAQ Global market under the symbol “KITE.”
In December 2014, Kite Pharma sold 4,007,750 shares of it common stock in their follow-on offering <https://en.wikipedia.org/wiki/Follow-on_offering> at $54.00 per share, for gross proceeds of $216.4 million. <https://en.wikipedia.org/wiki/Kite_Pharma#cite_note-43>
Forget Harvey victims—send them your money!! Remember how beloved our friends at Gilead are!
Let alone the black box on that stuff looks worse than the disease! They need more money.
Poor dears must be suffering so!!
George M. Carter
> On Sep 1, 2017, at 3:33 PM, Jamie Love <james.love at keionline.org> wrote:
> David Mitchell pointed me to this one.
> Dr. June said that producing engineered T-cells costs about $20,000 per
> patient — far less than the cost of a bone-marrow transplant. Scaling up
> the procedure should make it even less expensive, he said, but he added,
> “Our costs do not include any profit margin, facility depreciation costs or
> other clinical care costs, and other research costs.”
More information about the Ip-health